Eko Health Stock
| Valuation | $271.32M1 |
| Valuation Date | Jun 5, 2024 |
| Implied Valuation | n/a |
| Last Price | $1.60 |
| 52-Week High | $1.60 |
| 52-Week Low | $1.60 |
| YTD Return | +0.00% |
| 1-Year Return | +0.00% |
| 3-Year Return | n/a |
| Total Funding | $165M2 |
| Latest Round Amount | $41M3 |
| Latest Round | Series D |
| Funding Rounds | 6 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Eko Health
Eko Health is a digital health company that develops AI-powered stethoscopes for detecting heart and lung disease. Its digital stethoscopes and ECG devices capture heart sounds and electrical signals during a routine physical exam. The company's FDA-cleared SENSORA platform then analyzes the recordings to flag signs of structural heart murmurs, atrial fibrillation and low ejection fraction, a key indicator of heart failure. Eko makes money by selling its devices along with software subscriptions to clinicians, hospitals and health systems, and more than 700,000 of its devices have been sold worldwide.
Invest in Eko Health
Eko Health is a private company, so you can't purchase it with a regular brokerage account. However, its shares are available on Hiive.
Hiive is a secondary marketplace where accredited investors can buy and sell shares of private, pre-IPO companies. Invest in the world's most exciting startups before they go public.
Invest on HiiveStock Analysis may be compensated for user sign-ups through Hiive links. Hiive is not affiliated with Stock Analysis. Securities offered by Hiive Markets Limited, member of FINRA/SIPC.
Related Companies
News
Eko Health Surpasses 750,000 Digital Stethoscopes Sold
Eko Health announced it has sold 750,000 digital stethoscopes worldwide, underscoring adoption of its AI-enabled cardiac and pulmonary detection platform across health systems.
Eko Health Appoints Dr. Steven Steinhubl as Chief Medical Officer
Eko Health named cardiologist and digital medicine researcher Steven Steinhubl as Chief Medical Officer. He will lead the company's clinical strategy, research initiatives and scientific collaboration...
Boehringer Ingelheim and Eko Health Launch AI-Based Solution That Detects Heart Murmurs in Dogs
Boehringer Ingelheim and Eko Health launched Eko Vet+ | CANINEBEAT AI in April 2026 to help veterinarians detect, visualize, and grade heart murmurs in dogs, beginning rollout in the U.S. and UK.
Boehringer Ingelheim and Eko Health Launch AI-Powered Solution to Detect Heart Murmurs in Dogs
Eko Health and animal health company Boehringer Ingelheim launched Eko Vet+ with CANINEBEAT AI, a veterinary auscultation solution that detects and grades heart murmurs in dogs. The rollout began in t...
Wayne General Hospital Deploys Eko SENSORA in Rural Mississippi
Wayne General Hospital partnered with Eko Health to roll out the SENSORA AI cardiac detection platform across emergency and primary care departments in rural Mississippi.
Wayne General Hospital Partners with Eko Health to Deploy AI-Assisted Cardiac Detection in Rural Mississippi
Wayne General Hospital in Mississippi partnered with Eko Health to deploy the SENSORA cardiac detection platform across its emergency and primary care departments, bringing AI-assisted stethoscope exa...
The Lancet Publishes TRICORDER Study on AI Stethoscopes in Primary Care
The Lancet published the TRICORDER study, a cluster-randomised trial across 205 NHS practices led by Imperial College London. Patients examined with Eko's AI stethoscopes saw detection increase 2.3x f...
Dr. Steven Steinhubl Joins Eko Health as Chief Medical Officer
Eko Health appointed Steven R. Steinhubl, M.D., as chief medical officer to help scale AI-powered cardiac detection as the company expands its clinical footprint.
CMS Finalizes OPPS Payment for Eko Health's SENSORA Platform
The Centers for Medicare & Medicaid Services finalized national payment for Eko Health's SENSORA platform under the Outpatient Prospective Payment System, allowing hospitals to be reimbursed for AI-as...
FDA Clears Eko Health's EFAST Algorithm, the First Cardiovascular AI Foundation Model
The FDA cleared Eko Health's EFAST algorithm for use within the SENSORA platform. EFAST is described as the first FDA-cleared foundation model for cardiovascular AI and detects structural heart murmur...
CMS Recognizes Eko Health's AI-Powered Heart Disease Detection in OPPS July 2025 Update, Establishing Payment Rate for SENSORA
CMS included Eko's SENSORA platform in its July 2025 outpatient payment update, assigning a reimbursement rate of $128.00 per use for the AI cardiac detection technology.
Eko Health Announces Appointment of Brent Lang, Former CEO of Vocera, to Board of Directors
EMERYVILLE, Calif. , Sept. 12, 2024 /PRNewswire/ -- Eko Health , a pioneer in applying artificial intelligence (AI) for early detection of heart and lung diseases, today announced the appointment of B...
Eko Health scores $41M to detect heart and lung disease earlier and more accurately
Eko Health raised a $41 million Series D round with participation from ARTIS Ventures, Highland Capital Partners, NTTVC and Questa Capital, bringing total funding to $165 million. The capital funds AI...
Eko Health Receives FDA Clearance for Low Ejection Fraction AI
The FDA cleared Eko Health's Low EF detection AI, developed with Mayo Clinic, which lets providers detect low ejection fraction, a key heart failure indicator, in 15 seconds during a routine exam usin...
FIGS and Eko Health Collaborate on the FIGS | Eko CORE 500™ Digital Stethoscope
SANTA MONICA, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--FIGS, Inc. (NYSE: FIGS), the direct-to-consumer healthcare apparel and lifestyle brand, and Eko Health, Inc. (“Eko”), a leading innovator in...
Astellas and Eko Health Announce Agreement to Incorporate Next Generation Eko CORE 500™ Digital Stethoscope into Z1608, an Innovative Solution Under Development for Heart Failure Patients Built on Welldoc's Proven Digital Therapeutic Platform
TOKYO, EMERYVILLE, Calif. and COLUMBIA, Md.
Eko expands algorithmic heart problem detection and lands $30M Series C extension
Eko closed a $30 million extension to its Series C round, bringing total funding to $125 million. The extension supports commercialization efforts and new product development.
Eko Raises $65 Million in Series C Funding to Close the Gap Between Virtual and In-Person Heart and Lung Care
Eko announced $65 million in Series C funding led by Highland Capital Partners and Questa Capital, with participation from ARTIS Ventures, DigiTx Partners, NTTVC and 3M Ventures, to expand its telehea...
AI-Powered Digital Health Company Eko Closes $20 Million Series B to Continue the Fight Against Heart Disease
Eko secured $20 million in Series B funding led by ARTIS Ventures, with participation from DigiTx Partners, NTTVC, 3M Ventures, Mayo Clinic, Seraph Group and XTX Ventures, to fund research and commerc...